Mayaku Pharmaceutical Development SRL
1.3 FTEMayaku Pharmaceutical Development reported total assets of 170,483 € at the end of the 2025 financial year (annual accounts filed with the NBB on 04 Jul 2026), with 1.3 full-time equivalent.
The score of Mayaku Pharmaceutical Development shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -94 % Total assets +188 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Mayaku Pharmaceutical Development's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 04 Jul 2026
- Year ended 31 Dec 2024filed on 27 Jun 2025
- Year ended 31 Dec 2023filed on 18 Jun 2024
- Year ended 31 Dec 2022filed on 29 Jun 2023
- Year ended 31 Dec 2021filed on 19 Jul 2022
Mayaku Pharmaceutical Development's financial analysis
- Solvency0.8%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Mayaku Pharmaceutical Development
1 active director(s) in the register.
Mayaku Pharmaceutical Development's shareholders and holdings →Mayaku Pharmaceutical Development's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0755.350.975
- VAT number
- BE0755350975
- Peppol
- Registered · 0208:0755350975 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Sep 2020
- Registered office
- 9052 Ghent
- Size
- Micro · 1.3 FTE
- Latest accounts
- 2025 · filed on 04 Jul 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Mayaku Pharmaceutical Development (SRL) has been based in Ghent since 2020, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of 1,553 € and equity of 1,291 €; its revenue is not published. With 1.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 0.8%, below the median of its sector (56.0%).
Companies similar to Mayaku Pharmaceutical Development
Companies in the same business, of comparable size and area, outside its group.
- BelCoPhar Manufacture of pharmaceutical preparations Kalmthout · balance sheet 224,468 €
- Yaro Preclinical Consulting Manufacture of basic pharmaceutical products Turnhout · balance sheet 158,481 €
- Pharmacie Courouble Manufacture of basic pharmaceutical products Schaerbeek · balance sheet 129,672 €
- Orca Consulting Manufacture of pharmaceutical preparations Kapellen · balance sheet 347,741 €
- Medipharm Worldwide Group Manufacture of basic pharmaceutical products Tienen · balance sheet 331,081 €
- Montefalcone Projects Manufacture of basic pharmaceutical products Maarkedal · balance sheet 207,746 €
- huMAN Manufacture of basic pharmaceutical products Gerpinnes · balance sheet 186,227 €
- MDT Services & Technologies Manufacture of basic pharmaceutical products Lontzen · balance sheet 102,386 €
Frequently asked questions about Mayaku Pharmaceutical Development
What is the revenue of Mayaku Pharmaceutical Development?
Mayaku Pharmaceutical Development files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Mayaku Pharmaceutical Development?
In Belgium, the VAT number is the company number prefixed with BE: BE0755350975 for Mayaku Pharmaceutical Development, if the company is VAT-registered. Its company number (CBE) is 0755.350.975.
Where is the registered office of Mayaku Pharmaceutical Development?
According to the CBE register, the registered office of Mayaku Pharmaceutical Development is in 9052 Ghent.
What is the equity of Mayaku Pharmaceutical Development?
At the close of the 2025 financial year, the equity of Mayaku Pharmaceutical Development amounts to 1,291 €, a solvency of 0.8% of total assets.
How many people work at Mayaku Pharmaceutical Development?
1.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Mayaku Pharmaceutical Development?
The register lists 1 active mandates at Mayaku Pharmaceutical Development. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Mayaku Pharmaceutical Development
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →